Loading
Anika Therapeutics, Inc. Stock: price and insider trades · United States
1 insider bought €36k of shares over the last 90 days, the latest by Fischetti Gary P, filed 05 Aug 2026.
Anika Therapeutics, Inc.: what insiders have been doing
Anika Therapeutics, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 22 October 2025 and 22 October 2026, 10 insiders published 35 filings.
Not one open-market sale was filed. On the buying side, 2 insiders reported 3 purchases totalling €163k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. One trade stands out by size: a purchase of €128k from Griffin Stephen D., disclosed on 30 April 2026, or 0.052% of market capitalisation. Those buying include 1 senior executive and 1 chief executive.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 35 filings, this issuer sits above that mark. Since 2016, the database holds 13 purchases and 30 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 112.8 m USD and net income at -10.9 m USD.
The most recent open-market purchase was published on 5 August 2026, 79 days ago. Typically, a trade is published a median of 3 days after it takes place. US insiders must file a Form 4 within two business days of a trade.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
276
Thresholds
n/a
Buy Volume
€776,229
13 ops. · all time
Sell Volume
€9M
30 ops. · all time
Who traded when
BuySaleGary P. Fischetti2 buys
Stephen D. Griffin1 buy
Since the insiders bought
- +2.2%Entry US$20.16 · Close 21 Oct 2026 US$20.60
- +38.7%Entry US$14.85 · Close 21 Oct 2026 US$20.60
- +15.4%Entry US$22.28 · Close at T+365 US$25.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,848 of 26,248 companies
36.9
score / 100
Value35
Quality39
FCF yld1.6%
Earn yld-4.0%
EV/EBITDA·
ROE-2.2%
Gross mgn57%
Net mgn-9.6%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$20.44
Analyst consensus
2 analysts1.50/5
US$23.00Target US$23.00(+13%)US$23.00
Income statement
RevenueUS$112.8M
Gross profitUS$63.8M57% margin
EBITDA-US$5.3M-5% margin
Net income-US$10.9M-3.1% margin
Valuation
PER (forward)21.5x
P/Book2.0x
Beta0.21
Balance sheet & cash
Market capUS$273.5M
Total debtUS$26.2M
Free Cash FlowUS$4.4M
Debt / Equity18%
Profitability & ownership
ROE-2.2%
ROA-0.9%
% insiders6.4%
% institutions93.7%
Last declaration on 7 August 2026
Declarations276 total
16,864 shares@ US$21.06590.13% mcap100.0% of flowCommonSEC144:0001959173-26-005793
1,000 shares@ US$20.7450.0075% mcap50.5% of flowCommon StockSEC:0001193125-26-335269:0
Canonical exit: 1 Nov 2026 (T+90)
1,000 shares@ US$20.3150.0074% mcap49.5% of flowCommon StockSEC:0001193125-26-335269:1
Canonical exit: 2 Nov 2026 (T+90)
10,402 sharesCommon StockSEC:0001193125-26-279535:0
10,402 sharesCommon StockSEC:0001193125-26-279539:0
10,402 sharesCommon StockSEC:0001193125-26-279541:0
10,402 sharesCommon StockSEC:0001193125-26-279542:0
10,402 sharesCommon StockSEC:0001193125-26-279545:0
3,769 shares@ US$14.410.019% mcap26.8% of flowCommon StockSEC:0001193125-26-259520:1
12,840 sharesCommon StockSEC:0001193125-26-259520:0
12,200 shares@ US$12.28530.052% mcap73.2% of flowCommon StockSEC:0001193125-26-197887:0
Canonical exit: 29 Jul 2026 (T+90)
6,412 shares0Common StockSEC:0001193125-26-111502:1
4,694 shares0Common StockSEC:0001193125-26-111511:1
6,449 sharesCommon StockSEC:0001193125-26-111511:3
1,161 shares0Common StockSEC:0001193125-26-111492:1
2,658 sharesCommon StockSEC:0001193125-26-111492:3
24,520 shares0Common StockSEC:0001193125-26-111494:1
25,131 sharesCommon StockSEC:0001193125-26-111494:3
5,944 shares@ US$14.2025.6% of flowCommon StockSEC:0001193125-26-111502:2
4,168 shares@ US$14.209.9% of flowCommon StockSEC:0001193125-26-111511:2
1,893 shares@ US$14.204.5% of flowCommon StockSEC:0001193125-26-111511:4
1,449 shares@ US$14.2049.9% of flowCommon StockSEC:0001193125-26-111492:2
781 shares@ US$14.2026.9% of flowCommon StockSEC:0001193125-26-111492:4
14,728 shares@ US$14.207.1% of flowCommon StockSEC:0001193125-26-111494:2
12,104 shares@ US$14.205.9% of flowCommon StockSEC:0001193125-26-111494:4
25 of 276 declarations
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. is a U.S.-based company listed on the Nasdaq market (ticker: ANIK), making it a closely watched small-cap healthcare name for investors focused on orthopedics and medical technology in the United States. Headquartered in Bedford, Massachusetts, United States, the company was founded in 1992 as a spin-off of MedChem Products. Over time, Anika has built its identity around hyaluronic acid (HA) science, using that technology platform to develop products aimed at joint preservation, early-intervention orthopedics, and osteoarthritis pain management. ([sec.gov](https://www.sec.gov/Archives/edgar/data/898437/000117184324001380/anik20231231_10k.htm?utm_source=openai))
Anika’s business is centered on two main product families. The first is regenerative solutions for orthopedic repair: Integrity™ is an HA-based scaffold for rotator cuff and tendon repair, Hyalofast® is a single-stage cartilage repair scaffold, Tactoset® is an injectable HA-enhanced bone substitute, and NanoFx® supports advanced bone marrow stimulation. The second pillar is osteoarthritis pain management, led by Cingal® (a next-generation HA plus corticosteroid injection), Monovisc® and Orthovisc®, both HA-based viscosupplements used to relieve knee OA pain. This portfolio gives Anika a focused position in orthobiologics and joint-preservation care, rather than a broad hospital-supply or general orthopedics model. ([anika.com](https://anika.com/products/?utm_source=openai))
Read moreShow less
Commercially, the company combines direct and partner-led distribution. Anika highlights an international footprint, with certain products such as Cingal available in more than 45 countries through a global distributor network. In the U.S., Monovisc and Orthovisc are marketed and sold exclusively through J&J MedTech, while outside the U.S. they are sold through Anika’s commercial partners. That structure gives the company leverage in some markets while also limiting direct control in others, which is an important feature for investors assessing revenue mix and operating margin potential. ([anika.com](https://anika.com/about-anika/?utm_source=openai))
Recent company updates have been centered on pipeline progress and a more disciplined cost structure. In 2025, Anika reported positive developments for Hyalofast, including the filing of the third and final PMA module with the FDA, and continued work toward an NDA submission for Cingal. Management also announced a $15 million share repurchase program in 2025 and, in early 2026, described actions to reduce general and administrative expenses as part of a broader operational transformation. The latest results also pointed to improving commercial momentum in its direct channel and continued focus on profitability. Overall, Anika remains a specialized orthopedic platform story, with value creation tied to regulatory execution, product adoption, and the conversion of its HA pipeline into durable growth. ([ir.anika.com](https://ir.anika.com/2025-11-05-Anika-Reports-Third-Quarter-2025-Financial-Results?asPDF=1&utm_source=openai))
